IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration
Cancer Pain
About this trial
This is an interventional treatment trial for Cancer Pain focused on measuring Orally, IV PCA with continuous + bolus dose, IV PCA with bolus-only dose
Eligibility Criteria
Inclusion Criteria:
- The patients were 18-80 years old and diagnosed as malignant solid tumor by pathology;
- Patients with persistent cancer pain and NRS score ≥ 7 during previous 24 hours;
- Patients who did not receive radiotherapy, chemotherapy or targeted therapy within 7 days before randomization and trial;
- Patients or his/her caregivers who are able to fill out the questionnaire forms ;
- Ability to correctly understand and cooperate with medication guidance of doctors and nurses ;
- Without psychiatric problems;
- ECOG performance status ≤3;
- Patients who did not receive the trial drug within 14 days before the trial;
- The subjects voluntarily signed the informed consent.
Exclusion Criteria:
- The pain is confirmed not due to cancer;
- Patients with severe post-operative pain;
- Patients with paralytic ileus;
- Patients with brain metastasis;
- Patients hypersensitive to opioids;
- Patients with abnormal lab results that have obvious clinical significance, such as creatine ≥ 2 fold of upper limit of normal value, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 fold of upper limit of normal value, or liver function of Child C grade;
- Patients who cannot take drugs orally;
- Patients with an incoercible nausea or vomiting;
- Those who have received monoamine oxidase inhibitor (MAOI) within two weeks before randomization;
- Patients who are pregnant or in lactation, or who plan to be pregnant within one month after the trial;
- Alcoholic patients;
- Patients with other conditions or reasons causing the patients unable to complete the clinical trial.
Sites / Locations
- China, Fujian
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
PCA with continuous + bolus dose
PCA with bolus-only dose
Oral opioid
(1)Intravenous PCA with hydromorphone after successful titration of 24 hours;(2)PCA hydromorphone with continuous infusion where dose/h was the total equianalgesic over the previous 24h divided by 24 and bolus dosage for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h;lockout time = 10 minutes;(3)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
(1)Intravenous PCA with hydromorphone after successful titration of 24 hours; (2)PCA hydromorphone with bolus-only where dosage was 10%-20% of the total equianalgesic over the previous 24h administrated as needed;(3)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
(1)Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours;(2)Oral sustained-released morphine where total equianalgesic over the previous 24h/2×75% every 12h/day and immediate-release morphine for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h; (3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day;(4)The treatment regimen was continued for 7 days.